MEI Pharma announces new clinical data from First-In-Human Study of ME-401
MEI Pharma, the San Diego based oncology company, have today announced new clinical data from a First-In-Human study for ME-401, a next generation oral PI3K delta inhibitor.
Going the extra mile in aid of the Teenage Cancer Trust
On Friday 15th April, two determined Quotient Clinical employees, David Ross and Pete Knight, set off on a challenging cycle ride, from Nottingham to Edinburgh, in support of the Teenage Cancer Trust. The journey, approximately 300 miles over 4 days, was designed to cover the distance between the company’s headquarters in Ruddington, Nottingham and their Data Sciences facility in Edinburgh.
Quotient Clinical extends spray drying capabilities for poorly soluble molecules
Quotient Clinical, the Translational Pharmaceutics company, has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor™ Spray Dryer.
A special Easter delivery for children at Teenage Cancer Trust unit, Nottingham
Young patients spending the Easter period in hospital got a special treat thanks to a generous donation from Quotient Clinical employees in Nottingham and Edinburgh.
Quotient Clinical incorporates Japanese bridging into a Translational Pharmaceutics® program
Quotient Clinical, the Translational Pharmaceutics company, has announced the completion of its first clinical program involving Japanese healthy volunteers.
Quotient Clinical celebrates its 100th RapidFACT® program
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT® (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues.